3. Program Goals

4. Overview

5. Glatiramer Acetate 3 Times a Week

6. Glatiramer Acetate 3 Times a Week (cont)

7. Glatiramer Acetate 3 Times a Week (cont): Safety

8. Glatiramer Acetate: Generic Formulation

9. Pegylated Interferon for MS

10. Pegylated Interferon (cont): Pharmacokinetics

11. Pegylated Interferon (cont): ADVANCE Phase 3 Study

12. Clinical Impact of New Injectable Formulations

13. Oral Therapies for MS

14. Oral Therapies: Mechanisms

15. Oral Therapies: Efficacy

16. Oral Therapies: Safety

17. Oral vs Standard Therapies

18. Considerations in Selecting Oral Therapy

19. Switching to an Oral Agent: Counseling Considerations

20. Switching to an Oral Agent: Is a Washout Period Necessary?

21. Looking Ahead

22. Looking Ahead (cont)

23. Summary and Key Points

24. Abbreviations

25. References

26. References (cont)